Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Oct;26(4):429–434. doi: 10.1111/j.1365-2125.1988.tb03402.x

Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

R O Day 1, J Miners 1, D J Birkett 1, G G Graham 1, A Whitehead 1
PMCID: PMC1386565  PMID: 3190993

Abstract

1. 1-methyl xanthine (1-MX) is metabolized exclusively to 1-methyl uric acid (1-MU) by the enzyme xanthine oxidase. 2. The ratio of 1-MU to 1-MX in the urine, following a dose of 50 mg of 1-MX infused intravenously over 20 min, was used to measure the inhibition of xanthine oxidase induced by different doses of allopurinol. 3. Normal volunteers (n = 8) were given allopurinol 50, 100, 300 and 600 mg daily for 1 week each, in random order and 1 week separated each treatment. Inhibition of xanthine oxidase was assessed twice, on the last 2 days of each treatment week. 4. Steady-state oxipurinol concentrations increased linearly with increasing dose of allopurinol. 5. There was a hyperbolic relationship between the 1-MU/1-MX ratio and plasma oxipurinol concentrations, with an initial steep decline in the ratio which plateaued when plasma oxipurinol was around 4-6 mg l-1. This reduction in the ratio was quickly reversible upon cessation of allopurinol. 6. The 50% and 90% effective inhibitory oxipurinol concentrations, in relation to the 1-MU-/1-MX ratio were 1.4 +/- 0.46 and 4.08 +/- 2.03 mg l-1 respectively. 7. The concentration of oxipurinol required for almost complete inhibition of the enzyme was substantially less than those often observed in clinical practice.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auscher C., Pasquier C., Mercier N., Delbarre F. Urinary excretion of 6 hydroxylated metabolite and oxypurines in a xanthinuric man given allopurinol or thiopurinol. Adv Exp Med Biol. 1974;41:663–667. doi: 10.1007/978-1-4757-1433-3_37. [DOI] [PubMed] [Google Scholar]
  2. BERGMANN F., DIKSTEIN S. Studies on uric acid and related compounds. III. Observations on the specificity of mammalian xanthine oxidases. J Biol Chem. 1956 Dec;223(2):765–780. [PubMed] [Google Scholar]
  3. Birkett D. J., Dahlqvist R., Miners J. O., Lelo A., Billing B. Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos. 1985 Nov-Dec;13(6):725–728. [PubMed] [Google Scholar]
  4. Birkett D. J., Miners J. O., Attwood J. Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid. Br J Clin Pharmacol. 1983 Jan;15(1):117–119. doi: 10.1111/j.1365-2125.1983.tb01475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chalmers R. A., Parker R., Simmonds H. A., Snedden W., Watts R. W. The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase. Biochem J. 1969 May;112(4):527–532. doi: 10.1042/bj1120527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. ENGELMAN K., WATTS R. W., KLINENBERG J. R., SJOERDSMA A., SEEGMILLER J. E. CLINICAL, PHYSIOLOGICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH XANTHINURIA AND PHEOCHROMOCYTOMA. Am J Med. 1964 Dec;37:839–861. doi: 10.1016/0002-9343(64)90128-7. [DOI] [PubMed] [Google Scholar]
  7. Elion G. B., Kovensky A., Hitchings G. H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966 Jul;15(7):863–880. doi: 10.1016/0006-2952(66)90163-8. [DOI] [PubMed] [Google Scholar]
  8. Emmerson B. T., Gordon R. B., Cross M., Thomson D. B. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987 Dec;26(6):445–449. doi: 10.1093/rheumatology/26.6.445. [DOI] [PubMed] [Google Scholar]
  9. Grant D. M., Tang B. K., Campbell M. E., Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol. 1986 Apr;21(4):454–458. doi: 10.1111/j.1365-2125.1986.tb05222.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grant D. M., Tang B. K., Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983 May;33(5):591–602. doi: 10.1038/clpt.1983.80. [DOI] [PubMed] [Google Scholar]
  11. Hande K. R., Noone R. M., Stone W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. doi: 10.1016/0002-9343(84)90743-5. [DOI] [PubMed] [Google Scholar]
  12. Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
  13. Jackson P. R., Tucker G. T., Lennard M. S., Woods H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol. 1986 Nov;22(5):541–550. doi: 10.1111/j.1365-2125.1986.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kramer W. G., Feldman S. High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma. J Chromatogr. 1979 Jan 1;162(1):94–97. doi: 10.1016/s0378-4347(00)82068-x. [DOI] [PubMed] [Google Scholar]
  15. Krenitsky T. A., Neil S. M., Elion G. B., Hitchings G. H. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys. 1972 Jun;150(2):585–599. doi: 10.1016/0003-9861(72)90078-1. [DOI] [PubMed] [Google Scholar]
  16. Lohmann S. M., Miech R. P. Theophylline metabolism by the rat liver microsomal system. J Pharmacol Exp Ther. 1976 Jan;196(1):213–225. [PubMed] [Google Scholar]
  18. Pedersen P. V. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm. 1977 Oct;5(5):513–531. doi: 10.1007/BF01061732. [DOI] [PubMed] [Google Scholar]
  19. Simmonds H. A., Levin B., Cameron J. S. Variations in allopurinol metabolism by xanthinuric subjects. Clin Sci Mol Med. 1974 Aug;47(2):173–178. doi: 10.1042/cs0470173. [DOI] [PubMed] [Google Scholar]
  20. Simmonds H. A. Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol. Clin Chim Acta. 1969 Feb;23(2):353–364. doi: 10.1016/0009-8981(69)90052-7. [DOI] [PubMed] [Google Scholar]
  21. Spector T. Inhibition of urate production by allopurinol. Biochem Pharmacol. 1977 Mar 1;26(5):355–358. doi: 10.1016/0006-2952(77)90191-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES